Company news

uniQure N.V. news in 2024

uniQure N.V.'s news releases, calls and decks from 2024, newest first.

View company

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

December 9, 2024

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

November 20, 2024

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

November 4, 2024

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

October 14, 2024

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

September 22, 2024

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

August 14, 2024

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

July 31, 2024

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

July 22, 2024

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease

July 8, 2024

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen

June 30, 2024

uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease

June 2, 2024

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

May 6, 2024

uniQure Announces 2023 Financial Results and Highlights Recent Company Progress

February 27, 2024

Decks in 2024